Another pharmaceutical equipment company achieved double growth in revenue and net profit in the first half of the year!

[Pharmaceutical Network Industry News] On August 30, Tofflon released the 2022 semi-annual report summary.
In the first half of the year, the company achieved an operating income of about 2.
4 billion yuan, a year-on-year increase of 34.
11%; the net profit attributable to shareholders of the listed company was about 400 million yuan.
Yuan, a year-on-year increase of 18.
33%
.

This report card is in line with Tofflon's expectation on the evening of July 11 that "the net profit attributable to the parent in the first half of the year is 391 million yuan to 425 million yuan, a year-on-year increase of 15%-25%"
.

Regarding the reasons for the growth in performance, the announcement stated that during the reporting period, the company's pharmaceutical equipment product diversified layout and internationalization strategy achieved results, and the multi-field products such as injections, solid preparations, biological macromolecules, cells and genetic equipment grew steadily during the reporting period.

.

At the same time, the company overcame various difficulties, carried out production and manufacturing in an orderly manner, and actively took measures to reduce the adverse impact on the company's production and operation
.

The report shows that Tofflon adheres to the mission of "professional technology serves human health", and focuses on the development strategy of "systematization, internationalization, and digital intelligence" to provide global customers with forward-looking and competitive pharmaceutical equipment and food equipment.
, cell and gene therapy equipment, food equipment and other system solutions
.

 　　The recent period is a period of intensive disclosure of semi-annual reports by listed companies.
In addition to Tofflon, there are still a number of pharmaceutical equipment companies that have increased their performance in the first half of the year
.

 　　For example, Xinlai Yingcai disclosed its semi-annual report on the evening of August 29.
The company achieved operating income of 1.
224 billion yuan in the first half of the year, a year-on-year increase of 36.
57%; net profit of 156 million yuan, a year-on-year increase of 129.
91%; basic earnings per share of 0.
69 yuan
.

 　　On August 27, the 2022 semi-annual report disclosed by Chutian Technology showed that from January to June 2022, the operating income was 2.
871 billion yuan, a year-on-year increase of 20.
04%, and the net profit attributable to shareholders of the listed company was 299 million yuan, a year-on-year increase of 26.
74%.
, earnings per share was 0.
5207 yuan
.

 　　Also on the 27th, Canaan Technology released the 2022 semi-annual report.
The company achieved operating income of 494 million yuan, a year-on-year increase of 14.
33%; realized a net profit attributable to shareholders of the listed company of 42.
3643 million yuan, a year-on-year increase of 12.
63%; realized the attributable to the listing.
The company's shareholders' net profit after deducting non-recurring gains and losses was 39.
4911 million yuan, a year-on-year increase of 19.
86%
.

 　　But some are happy and some are sad
.

For example, Xinhua Medical disclosed its 2022 semi-annual report on the evening of August 19, showing that the company achieved operating income of 4.
435 billion yuan in the first half of the year, a year-on-year decrease of 18.
77%; the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 352 million yuan , a year-on-year increase of 30.
67%
.

 　　Overall, most pharmaceutical equipment companies performed well in the first half of this year, and during the reporting period, many companies increased their R&D investment and increased new product development
.

For example, Chutian Technology invested 232 million yuan in R&D in the first half of the year, a year-on-year increase of 17.
32%.
The company plans to complete the development of 50 new products in 2022; Canaan Technology invested 31.
6448 million yuan in research and development, an increase of 13.
58% year-on-year.
More achievements have been made in the layout of the intellectual property field
.

 　　In addition, the field of biopharmaceuticals is being overweighted by leading pharmaceutical machine companies.
For example, during the reporting period, Chutian Technology established a holding subsidiary, Chutiansiweikang, which basically completed the preparation of stock solution and gene and cell therapy drugs in the front-end of biopharmaceuticals.
As for the equipment layout of production, Xinhua Medical also clarified in the report that the company's product structure in the pharmaceutical equipment sector has expanded from pharmaceutical equipment to the field of life sciences, focusing on the development of traditional Chinese medicine equipment and life science-related process equipment
.

 　　CITIC Securities stated in the research report that the global pharmaceutical equipment industry continues to iterate with the advancement of downstream treatment technologies.
The commercialization of emerging technologies represented by cell gene therapy and multispecific drugs has great potential and is expected to drive the rapid expansion of global upstream demand for biological drugs.
, catalyzing the further transformation of leading enterprises into integrated full-process service providers
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.